In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Roche acquires Disetronic for CHF1.66bn

25 Mar 2003

Executive Summary

Roche, the world's leading diabetes glucose testing manufacturer, is acquiring the second largest insulin pump maker Disetronic in a deal worth about CHF1.6bn ($1.2bn). For each Disetronic share, it provides two non-voting Roche shares plus CHF670 ($493.8) in cash.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
  • Medical Devices
    • Implantable Devices
    • Infusion Therapy Equipment and Supplies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By